Vivesto AB Logo

Vivesto AB

0N4A.L

(0.0)
Stock Price

0,31 SEK

-67.77% ROA

-49.48% ROE

-1.3x PER

Market Cap.

48.746.580,00 SEK

0% DER

0% Yield

-1947.14% NPM

Vivesto AB Stock Analysis

Vivesto AB Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Vivesto AB Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Vivesto AB Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Vivesto AB Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Unknown
2 MACD Unknown
3 RSI Unknown
4 Stoch RSI Unknown

Vivesto AB Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Vivesto AB Revenue
Year Revenue Growth
2011 64.283.000
2012 46.425.000 -38.47%
2013 29.728.000 -56.17%
2014 19.020.000 -56.3%
2015 23.100.000 17.66%
2016 7.195.000 -221.06%
2017 12.326.000 41.63%
2018 10.411.000 -18.39%
2020 482.000 -2059.96%
2021 26.192.000 98.16%
2022 1.014.999 -2480.5%
2023 26.140.000 96.12%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Vivesto AB Research and Development Expenses
Year Research and Development Expenses Growth
2011 38.748.000
2012 50.216.000 22.84%
2013 71.162.000 29.43%
2014 74.028.000 3.87%
2015 96.884.000 23.59%
2016 89.964.000 -7.69%
2017 56.389.000 -59.54%
2018 57.032.000 1.13%
2020 13.023.000 -337.93%
2021 65.569.999 80.14%
2022 17.996.000 -264.36%
2023 12.648.000 -42.28%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Vivesto AB General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Vivesto AB EBITDA
Year EBITDA Growth
2011 -60.469.000
2012 -64.736.999 6.59%
2013 -97.397.000 33.53%
2014 -102.312.000 4.8%
2015 -127.889.000 20%
2016 -136.176.000 6.09%
2017 -100.413.000 -35.62%
2018 -120.419.000 16.61%
2020 -109.645.000 -9.83%
2021 -144.145.000 23.93%
2022 -107.067.000 -34.63%
2023 -92.784.000 -15.39%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Vivesto AB Gross Profit
Year Gross Profit Growth
2011 54.156.000
2012 40.288.000 -34.42%
2013 22.893.000 -75.98%
2014 8.958.000 -155.56%
2015 18.324.000 51.11%
2016 2.806.000 -553.03%
2017 7.923.000 64.58%
2018 265.000 -2889.81%
2020 -102.766.000 100.26%
2021 -173.018.000 40.6%
2022 -359.359.001 51.85%
2023 -169.504.000 -112.01%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Vivesto AB Net Profit
Year Net Profit Growth
2011 -65.670.000
2012 -72.381.000 9.27%
2013 -105.112.000 31.14%
2014 -117.497.000 10.54%
2015 -141.539.000 16.99%
2016 -160.243.000 11.67%
2017 -118.007.000 -35.79%
2018 -201.305.000 41.38%
2020 -140.270.000 -43.51%
2021 -132.722.000 -5.69%
2022 -356.612.000 62.78%
2023 -257.440.000 -38.52%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Vivesto AB Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 -1
2012 -1 0%
2013 -1 0%
2014 -1 0%
2015 -1 0%
2016 -1 0%
2017 -1 0%
2018 -1 100%
2020 0 0%
2021 0 0%
2022 -1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Vivesto AB Free Cashflow
Year Free Cashflow Growth
2011 -55.353.000
2012 -76.374.000 27.52%
2013 -89.037.000 14.22%
2014 -111.286.000 19.99%
2015 -130.100.000 14.46%
2016 -133.526.000 2.57%
2017 -124.049.000 -7.64%
2018 -121.334.000 -2.24%
2020 -140.942.000 13.91%
2021 -179.914.000 21.66%
2022 -86.013.000 -109.17%
2023 -10.288.000 -736.05%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Vivesto AB Operating Cashflow
Year Operating Cashflow Growth
2011 -52.439.000
2012 -71.946.000 27.11%
2013 -86.899.000 17.21%
2014 -107.665.000 19.29%
2015 -128.126.000 15.97%
2016 -133.011.000 3.67%
2017 -123.634.000 -7.58%
2018 -118.839.000 -4.03%
2020 -136.576.000 12.99%
2021 -145.565.000 6.18%
2022 -85.736.000 -69.78%
2023 -10.288.000 -733.36%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Vivesto AB Capital Expenditure
Year Capital Expenditure Growth
2011 2.914.000
2012 4.428.000 34.19%
2013 2.138.000 -107.11%
2014 3.621.000 40.96%
2015 1.974.000 -83.43%
2016 515.000 -283.3%
2017 415.000 -24.1%
2018 2.495.000 83.37%
2020 4.366.000 42.85%
2021 34.349.000 87.29%
2022 277.000 -12300.36%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Vivesto AB Equity
Year Equity Growth
2011 273.474.000
2012 319.153.000 14.31%
2013 281.907.000 -13.21%
2014 375.710.000 24.97%
2015 326.053.000 -15.23%
2016 300.371.000 -8.55%
2017 345.036.000 12.95%
2018 383.499.000 10.03%
2020 680.197.000 43.62%
2021 549.713.000 -23.74%
2022 326.159.000 -68.54%
2023 197.799.000 -64.89%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Vivesto AB Assets
Year Assets Growth
2011 349.807.000
2012 453.263.000 22.82%
2013 468.383.000 3.23%
2014 514.568.999 8.98%
2015 515.578.999 0.2%
2016 521.582.999 1.15%
2017 568.075.000 8.18%
2018 605.040.000 6.11%
2020 863.542.000 29.94%
2021 594.308.000 -45.3%
2022 348.443.000 -70.56%
2023 220.673.000 -57.9%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Vivesto AB Liabilities
Year Liabilities Growth
2011 76.333.000
2012 133.219.000 42.7%
2013 186.476.000 28.56%
2014 138.858.000 -34.29%
2015 189.526.000 26.73%
2016 221.212.000 14.32%
2017 223.039.000 0.82%
2018 188.719.000 -18.19%
2020 183.345.000 -2.93%
2021 44.595.000 -311.13%
2022 22.284.000 -100.12%
2023 22.874.000 2.58%

Vivesto AB Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.24
Price to Earning Ratio
-1.3x
Price To Sales Ratio
7.37x
POCF Ratio
-2.43
PFCF Ratio
-0.7
Price to Book Ratio
0.84
EV to Sales
6.72
EV Over EBITDA
-0.55
EV to Operating CashFlow
-0.65
EV to FreeCashFlow
-0.64
Earnings Yield
-0.77
FreeCashFlow Yield
-1.42
Market Cap
0,05 Bil.
Enterprise Value
0,04 Bil.
Graham Number
1.41
Graham NetNet
0.1

Income Statement Metrics

Net Income per Share
-0.24
Income Quality
0.53
ROE
-0.49
Return On Assets
-0.58
Return On Capital Employed
-0.71
Net Income per EBT
1
EBT Per Ebit
0.91
Ebit per Revenue
-21.38
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.96
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
-8.1
Operating Profit Margin
-21.38
Pretax Profit Margin
-19.47
Net Profit Margin
-19.47

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.13
Free CashFlow per Share
-0.13
Capex to Operating CashFlow
0.01
Capex to Revenue
-0.1
Capex to Depreciation
-0.01
Return on Invested Capital
-0.71
Return on Tangible Assets
-0.68
Days Sales Outstanding
115.48
Days Payables Outstanding
16.73
Days of Inventory on Hand
-19.19
Receivables Turnover
3.16
Payables Turnover
21.82
Inventory Turnover
-19.02
Capex per Share
-0

Balance Sheet

Cash per Share
0,14
Book Value per Share
0,37
Tangible Book Value per Share
0.31
Shareholders Equity per Share
0.37
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.05
Current Ratio
3.51
Tangible Asset Value
0,17 Bil.
Net Current Asset Value
0,06 Bil.
Invested Capital
0
Working Capital
0,06 Bil.
Intangibles to Total Assets
0.14
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-1582000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Vivesto AB Dividends
Year Dividends Growth

Vivesto AB Profile

About Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

CEO
Mr. Erik Kinnman Assoc. Prof.
Employee
14
Address
Gustav III:s Boulevard 46
Solna, 169 73

Vivesto AB Executives & BODs

Vivesto AB Executives & BODs
# Name Age
1 Mr. Dzianis Babrou
Head of Product Development
70
2 Ms. Kia Bengtsson
Head of Clinical Development
70
3 Ms. Johanna Rostin
Chief Regulatory Officer
70
4 Mr. Urban Ekelund
IR Manager
70
5 Maria Nilsson Hagberg
Head of Regulatory Affairs
70
6 Mr. Erik Kinnman Assoc. Prof., M.B.A., M.D., Ph.D.
Chief Executive Officer
70
7 Mr. Robert Maiorana
Head of Accounting & Acting Chief Financial Officer
70
8 Mr. John T. Cosby
Head of Regulatory Affairs
70
9 Mr. Henrik Rönnberg
Chief Medical Officer of Animal Health
70
10 Dr. Heidi B. Ramstad
Chief Medical Officer
70

Vivesto AB Competitors